#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=HIV/AIDS continues to be one of the most challenging individual and public health concerns of our days .
1-1	0-8	HIV/AIDS	abstract	new	coref	11-22
1-2	9-18	continues	_	_	_	_
1-3	19-21	to	_	_	_	_
1-4	22-24	be	_	_	_	_
1-5	25-28	one	abstract[2]	new[2]	_	_
1-6	29-31	of	abstract[2]	new[2]	_	_
1-7	32-35	the	abstract[2]|abstract[4]	new[2]|new[4]	_	_
1-8	36-40	most	abstract[2]|abstract[4]	new[2]|new[4]	_	_
1-9	41-52	challenging	abstract[2]|abstract[4]	new[2]|new[4]	_	_
1-10	53-63	individual	abstract[2]|abstract[4]	new[2]|new[4]	_	_
1-11	64-67	and	abstract[2]|abstract[4]	new[2]|new[4]	_	_
1-12	68-74	public	abstract[2]|abstract[4]	new[2]|new[4]	_	_
1-13	75-81	health	abstract[2]|abstract|abstract[4]	new[2]|new|new[4]	_	_
1-14	82-90	concerns	abstract[2]|abstract[4]	new[2]|new[4]	_	_
1-15	91-93	of	abstract[2]|abstract[4]	new[2]|new[4]	_	_
1-16	94-97	our	abstract[2]|abstract[4]|person|time[6]	new[2]|new[4]|acc|new[6]	_	_
1-17	98-102	days	abstract[2]|abstract[4]|time[6]	new[2]|new[4]|new[6]	_	_
1-18	103-104	.	_	_	_	_

#Text=According to the latest UNAIDS data , in 2018 , roughly 37.9 million individuals were infected with HIV globally , while around 770,000 people died of AIDS-related illness .
2-1	105-114	According	_	_	_	_
2-2	115-117	to	_	_	_	_
2-3	118-121	the	abstract[8]	new[8]	_	_
2-4	122-128	latest	abstract[8]	new[8]	_	_
2-5	129-135	UNAIDS	organization|abstract[8]	new|new[8]	_	_
2-6	136-140	data	abstract[8]	new[8]	_	_
2-7	141-142	,	_	_	_	_
2-8	143-145	in	_	_	_	_
2-9	146-150	2018	time	new	_	_
2-10	151-152	,	_	_	_	_
2-11	153-160	roughly	person[10]	new[10]	_	_
2-12	161-165	37.9	person[10]	new[10]	_	_
2-13	166-173	million	person[10]	new[10]	_	_
2-14	174-185	individuals	person[10]	new[10]	_	_
2-15	186-190	were	_	_	_	_
2-16	191-199	infected	_	_	_	_
2-17	200-204	with	_	_	_	_
2-18	205-208	HIV	abstract	new	coref	9-19
2-19	209-217	globally	_	_	_	_
2-20	218-219	,	_	_	_	_
2-21	220-225	while	_	_	_	_
2-22	226-232	around	quantity[12]	new[12]	_	_
2-23	233-240	770,000	quantity[12]	new[12]	_	_
2-24	241-247	people	quantity[12]	new[12]	_	_
2-25	248-252	died	_	_	_	_
2-26	253-255	of	_	_	_	_
2-27	256-268	AIDS-related	abstract[13]	new[13]	coref	4-13[20_13]
2-28	269-276	illness	abstract[13]	new[13]	_	_
2-29	277-278	.	_	_	_	_

#Text=During that same year , an estimated 1.7 million new infections occurred , mainly due to unprotected sexual intercourse .
3-1	279-285	During	_	_	_	_
3-2	286-290	that	time[14]	new[14]	_	_
3-3	291-295	same	time[14]	new[14]	_	_
3-4	296-300	year	time[14]	new[14]	_	_
3-5	301-302	,	_	_	_	_
3-6	303-305	an	quantity[15]	new[15]	coref	9-17[59_15]
3-7	306-315	estimated	quantity[15]	new[15]	_	_
3-8	316-319	1.7	quantity[15]	new[15]	_	_
3-9	320-327	million	quantity[15]	new[15]	_	_
3-10	328-331	new	quantity[15]	new[15]	_	_
3-11	332-342	infections	quantity[15]	new[15]	_	_
3-12	343-351	occurred	_	_	_	_
3-13	352-353	,	_	_	_	_
3-14	354-360	mainly	_	_	_	_
3-15	361-364	due	_	_	_	_
3-16	365-367	to	_	_	_	_
3-17	368-379	unprotected	event[16]	new[16]	_	_
3-18	380-386	sexual	event[16]	new[16]	_	_
3-19	387-398	intercourse	event[16]	new[16]	_	_
3-20	399-400	.	_	_	_	_

#Text=Investment in the field has been considerable , but a cure to the infection remains elusive .
4-1	401-411	Investment	abstract[17]	new[17]	_	_
4-2	412-414	in	abstract[17]	new[17]	_	_
4-3	415-418	the	abstract[17]|abstract[18]	new[17]|new[18]	coref	8-9[51_18]
4-4	419-424	field	abstract[17]|abstract[18]	new[17]|new[18]	_	_
4-5	425-428	has	_	_	_	_
4-6	429-433	been	_	_	_	_
4-7	434-446	considerable	_	_	_	_
4-8	447-448	,	_	_	_	_
4-9	449-452	but	_	_	_	_
4-10	453-454	a	event[19]	new[19]	_	_
4-11	455-459	cure	event[19]	new[19]	_	_
4-12	460-462	to	event[19]	new[19]	_	_
4-13	463-466	the	event[19]|abstract[20]	new[19]|giv[20]	coref	6-38[0_20]
4-14	467-476	infection	event[19]|abstract[20]	new[19]|giv[20]	_	_
4-15	477-484	remains	_	_	_	_
4-16	485-492	elusive	_	_	_	_
4-17	493-494	.	_	_	_	_

#Text=Nonetheless , tremendous advances have been made over the last 36 years since HIV-1 was identified , namely in prevention , diagnostics , and treatment .
5-1	495-506	Nonetheless	_	_	_	_
5-2	507-508	,	_	_	_	_
5-3	509-519	tremendous	abstract[21]	new[21]	_	_
5-4	520-528	advances	abstract[21]	new[21]	_	_
5-5	529-533	have	_	_	_	_
5-6	534-538	been	_	_	_	_
5-7	539-543	made	_	_	_	_
5-8	544-548	over	_	_	_	_
5-9	549-552	the	time[22]	new[22]	coref	7-18[46_22]
5-10	553-557	last	time[22]	new[22]	_	_
5-11	558-560	36	time[22]	new[22]	_	_
5-12	561-566	years	time[22]	new[22]	_	_
5-13	567-572	since	_	_	_	_
5-14	573-578	HIV-1	abstract	new	_	_
5-15	579-582	was	_	_	_	_
5-16	583-593	identified	_	_	_	_
5-17	594-595	,	_	_	_	_
5-18	596-602	namely	abstract[24]	new[24]	coref	8-10[0_24]
5-19	603-605	in	abstract[24]	new[24]	_	_
5-20	606-616	prevention	abstract[24]	new[24]	_	_
5-21	617-618	,	_	_	_	_
5-22	619-630	diagnostics	abstract	new	_	_
5-23	631-632	,	_	_	_	_
5-24	633-636	and	_	_	_	_
5-25	637-646	treatment	event	new	_	_
5-26	647-648	.	_	_	_	_

#Text=The development of antiretroviral drugs and the introduction of highly active antiretroviral therapy ( HAART ) in the mid-1990s — currently referred to as combination antiretroviral therapy ( cART ) — led to a dramatic shift of AIDS from a fatal disease into a chronic and often stable medical condition .
6-1	649-652	The	abstract[27]	new[27]	_	_
6-2	653-664	development	abstract[27]	new[27]	_	_
6-3	665-667	of	abstract[27]	new[27]	_	_
6-4	668-682	antiretroviral	abstract[27]|substance[28]	new[27]|new[28]	coref	8-1[49_28]
6-5	683-688	drugs	abstract[27]|substance[28]	new[27]|new[28]	_	_
6-6	689-692	and	abstract[27]	new[27]	_	_
6-7	693-696	the	abstract[27]|event[29]	new[27]|new[29]	_	_
6-8	697-709	introduction	abstract[27]|event[29]	new[27]|new[29]	_	_
6-9	710-712	of	abstract[27]|event[29]	new[27]|new[29]	_	_
6-10	713-719	highly	abstract[27]|event[29]|abstract[31]	new[27]|new[29]|new[31]	appos	6-15[0_31]
6-11	720-726	active	abstract[27]|event[29]|abstract[31]	new[27]|new[29]|new[31]	_	_
6-12	727-741	antiretroviral	abstract[27]|event[29]|abstract|abstract[31]	new[27]|new[29]|new|new[31]	coref	6-26
6-13	742-749	therapy	abstract[27]|event[29]|abstract[31]	new[27]|new[29]|new[31]	_	_
6-14	750-751	(	_	_	_	_
6-15	752-757	HAART	abstract	giv	coref	6-25[36_0]
6-16	758-759	)	_	_	_	_
6-17	760-762	in	_	_	_	_
6-18	763-766	the	time[33]	new[33]	_	_
6-19	767-776	mid-1990s	time[33]	new[33]	_	_
6-20	777-778	—	_	_	_	_
6-21	779-788	currently	_	_	_	_
6-22	789-797	referred	_	_	_	_
6-23	798-800	to	_	_	_	_
6-24	801-803	as	_	_	_	_
6-25	804-815	combination	abstract|abstract[36]	new|giv[36]	appos|coref	6-29[0_36]|18-25[176_0]
6-26	816-830	antiretroviral	abstract|abstract[36]	giv|giv[36]	coref	8-1
6-27	831-838	therapy	abstract[36]	giv[36]	_	_
6-28	839-840	(	_	_	_	_
6-29	841-845	cART	abstract	giv	coref	7-4
6-30	846-847	)	_	_	_	_
6-31	848-849	—	_	_	_	_
6-32	850-853	led	_	_	_	_
6-33	854-856	to	_	_	_	_
6-34	857-858	a	event[38]	new[38]	_	_
6-35	859-867	dramatic	event[38]	new[38]	_	_
6-36	868-873	shift	event[38]	new[38]	_	_
6-37	874-876	of	event[38]	new[38]	_	_
6-38	877-881	AIDS	event[38]|abstract	new[38]|giv	coref	18-22[175_0]
6-39	882-886	from	_	_	_	_
6-40	887-888	a	abstract[40]	new[40]	_	_
6-41	889-894	fatal	abstract[40]	new[40]	_	_
6-42	895-902	disease	abstract[40]	new[40]	_	_
6-43	903-907	into	abstract[40]	new[40]	_	_
6-44	908-909	a	abstract[40]|abstract[41]	new[40]|new[41]	_	_
6-45	910-917	chronic	abstract[40]|abstract[41]	new[40]|new[41]	_	_
6-46	918-921	and	abstract[40]|abstract[41]	new[40]|new[41]	_	_
6-47	922-927	often	abstract[40]|abstract[41]	new[40]|new[41]	_	_
6-48	928-934	stable	abstract[40]|abstract[41]	new[40]|new[41]	_	_
6-49	935-942	medical	abstract[40]|abstract[41]	new[40]|new[41]	_	_
6-50	943-952	condition	abstract[40]|abstract[41]	new[40]|new[41]	_	_
6-51	953-954	.	_	_	_	_

#Text=In fact , cART contributed decisively to a steady decrease in the number of HIV-related deaths since the first years of the new millennium .
7-1	955-957	In	_	_	_	_
7-2	958-962	fact	_	_	_	_
7-3	963-964	,	_	_	_	_
7-4	965-969	cART	abstract	giv	coref	11-1[67_0]
7-5	970-981	contributed	_	_	_	_
7-6	982-992	decisively	_	_	_	_
7-7	993-995	to	_	_	_	_
7-8	996-997	a	event[43]	new[43]	_	_
7-9	998-1004	steady	event[43]	new[43]	_	_
7-10	1005-1013	decrease	event[43]	new[43]	_	_
7-11	1014-1016	in	event[43]	new[43]	_	_
7-12	1017-1020	the	event[43]|quantity[44]	new[43]|new[44]	_	_
7-13	1021-1027	number	event[43]|quantity[44]	new[43]|new[44]	_	_
7-14	1028-1030	of	event[43]|quantity[44]	new[43]|new[44]	_	_
7-15	1031-1042	HIV-related	event[43]|quantity[44]|event[45]	new[43]|new[44]|new[45]	_	_
7-16	1043-1049	deaths	event[43]|quantity[44]|event[45]	new[43]|new[44]|new[45]	_	_
7-17	1050-1055	since	_	_	_	_
7-18	1056-1059	the	time[46]	giv[46]	_	_
7-19	1060-1065	first	time[46]	giv[46]	_	_
7-20	1066-1071	years	time[46]	giv[46]	_	_
7-21	1072-1074	of	time[46]	giv[46]	_	_
7-22	1075-1078	the	time[46]|time[47]	giv[46]|new[47]	_	_
7-23	1079-1082	new	time[46]|time[47]	giv[46]|new[47]	_	_
7-24	1083-1093	millennium	time[46]|time[47]	giv[46]|new[47]	_	_
7-25	1094-1095	.	_	_	_	_

#Text=Antiretroviral drugs have also been found useful in the prevention field , particularly in post-exposure prophylaxis or mother-to-child transmission .
8-1	1096-1110	Antiretroviral	object|substance[49]	giv|giv[49]	_	_
8-2	1111-1116	drugs	substance[49]	giv[49]	_	_
8-3	1117-1121	have	_	_	_	_
8-4	1122-1126	also	_	_	_	_
8-5	1127-1131	been	_	_	_	_
8-6	1132-1137	found	_	_	_	_
8-7	1138-1144	useful	_	_	_	_
8-8	1145-1147	in	_	_	_	_
8-9	1148-1151	the	abstract[51]	giv[51]	coref	17-15[160_51]
8-10	1152-1162	prevention	abstract|abstract[51]	giv|giv[51]	coref	10-25
8-11	1163-1168	field	abstract[51]	giv[51]	_	_
8-12	1169-1170	,	_	_	_	_
8-13	1171-1183	particularly	abstract[52]|abstract[53]	new[52]|new[53]	coref|coref	12-38[86_52]|12-38[87_53]
8-14	1184-1186	in	abstract[52]|abstract[53]	new[52]|new[53]	_	_
8-15	1187-1200	post-exposure	abstract[52]|abstract[53]	new[52]|new[53]	_	_
8-16	1201-1212	prophylaxis	abstract[52]|abstract[53]	new[52]|new[53]	_	_
8-17	1213-1215	or	abstract[53]	new[53]	_	_
8-18	1216-1231	mother-to-child	abstract[53]|abstract[54]	new[53]|new[54]	coref	12-57[93_54]
8-19	1232-1244	transmission	abstract[53]|abstract[54]	new[53]|new[54]	_	_
8-20	1245-1246	.	_	_	_	_

#Text=Treatment as prevention and pre-exposure prophylaxis ( PrEP ) have further contributed to the reduction of sexually transmitted HIV infections .
9-1	1247-1256	Treatment	abstract[55]	new[55]	_	_
9-2	1257-1259	as	abstract[55]	new[55]	_	_
9-3	1260-1270	prevention	abstract[55]	new[55]	_	_
9-4	1271-1274	and	abstract[55]	new[55]	_	_
9-5	1275-1287	pre-exposure	abstract[55]	new[55]	_	_
9-6	1288-1299	prophylaxis	abstract[55]	new[55]	_	_
9-7	1300-1301	(	_	_	_	_
9-8	1302-1306	PrEP	abstract	new	_	_
9-9	1307-1308	)	_	_	_	_
9-10	1309-1313	have	_	_	_	_
9-11	1314-1321	further	_	_	_	_
9-12	1322-1333	contributed	_	_	_	_
9-13	1334-1336	to	_	_	_	_
9-14	1337-1340	the	abstract[57]	new[57]	_	_
9-15	1341-1350	reduction	abstract[57]	new[57]	_	_
9-16	1351-1353	of	abstract[57]	new[57]	_	_
9-17	1354-1362	sexually	abstract[57]|quantity[59]	new[57]|giv[59]	_	_
9-18	1363-1374	transmitted	abstract[57]|quantity[59]	new[57]|giv[59]	_	_
9-19	1375-1378	HIV	abstract[57]|abstract|quantity[59]	new[57]|giv|giv[59]	coref	18-22
9-20	1379-1389	infections	abstract[57]|quantity[59]	new[57]|giv[59]	_	_
9-21	1390-1391	.	_	_	_	_

#Text=Long-lasting injectable products and antiretroviral-based microbicides that are currently in late stages of clinical development or regulatory approval may soon provide new options for prevention .
10-1	1392-1404	Long-lasting	_	_	_	_
10-2	1405-1415	injectable	object[60]	new[60]	coref	12-140[118_60]
10-3	1416-1424	products	object[60]	new[60]	_	_
10-4	1425-1428	and	_	_	_	_
10-5	1429-1449	antiretroviral-based	object[61]	new[61]	_	_
10-6	1450-1462	microbicides	object[61]	new[61]	_	_
10-7	1463-1467	that	_	_	_	_
10-8	1468-1471	are	_	_	_	_
10-9	1472-1481	currently	abstract[62]	new[62]	_	_
10-10	1482-1484	in	abstract[62]	new[62]	_	_
10-11	1485-1489	late	abstract[62]	new[62]	_	_
10-12	1490-1496	stages	abstract[62]	new[62]	_	_
10-13	1497-1499	of	abstract[62]	new[62]	_	_
10-14	1500-1508	clinical	abstract[62]|abstract[63]	new[62]|new[63]	coref	14-7[134_63]
10-15	1509-1520	development	abstract[62]|abstract[63]	new[62]|new[63]	_	_
10-16	1521-1523	or	abstract[62]	new[62]	_	_
10-17	1524-1534	regulatory	abstract[62]|abstract[64]	new[62]|new[64]	_	_
10-18	1535-1543	approval	abstract[62]|abstract[64]	new[62]|new[64]	_	_
10-19	1544-1547	may	_	_	_	_
10-20	1548-1552	soon	_	_	_	_
10-21	1553-1560	provide	_	_	_	_
10-22	1561-1564	new	abstract[65]	new[65]	_	_
10-23	1565-1572	options	abstract[65]	new[65]	_	_
10-24	1573-1576	for	_	_	_	_
10-25	1577-1587	prevention	abstract	giv	_	_
10-26	1588-1589	.	_	_	_	_

#Text=Gene therapy and the use of broadly neutralizing antibodies are also attracting a great deal of interest as possible approaches to HIV/AIDS management .
11-1	1590-1594	Gene	abstract[67]|abstract[68]	giv[67]|new[68]	coref|coref	12-36[0_67]|12-36[85_68]
11-2	1595-1602	therapy	abstract[67]|abstract[68]	giv[67]|new[68]	_	_
11-3	1603-1606	and	abstract[68]	new[68]	_	_
11-4	1607-1610	the	abstract[68]|abstract[69]	new[68]|new[69]	_	_
11-5	1611-1614	use	abstract[68]|abstract[69]	new[68]|new[69]	_	_
11-6	1615-1617	of	abstract[68]|abstract[69]	new[68]|new[69]	_	_
11-7	1618-1625	broadly	abstract[68]|abstract[69]|substance[70]	new[68]|new[69]|new[70]	_	_
11-8	1626-1638	neutralizing	abstract[68]|abstract[69]|substance[70]	new[68]|new[69]|new[70]	_	_
11-9	1639-1649	antibodies	abstract[68]|abstract[69]|substance[70]	new[68]|new[69]|new[70]	_	_
11-10	1650-1653	are	_	_	_	_
11-11	1654-1658	also	_	_	_	_
11-12	1659-1669	attracting	_	_	_	_
11-13	1670-1671	a	abstract[71]	new[71]	_	_
11-14	1672-1677	great	abstract[71]	new[71]	_	_
11-15	1678-1682	deal	abstract[71]	new[71]	_	_
11-16	1683-1685	of	abstract[71]	new[71]	_	_
11-17	1686-1694	interest	abstract[71]	new[71]	_	_
11-18	1695-1697	as	abstract[71]	new[71]	_	_
11-19	1698-1706	possible	abstract[71]	new[71]	_	_
11-20	1707-1717	approaches	abstract[71]	new[71]	_	_
11-21	1718-1720	to	abstract[71]	new[71]	_	_
11-22	1721-1729	HIV/AIDS	abstract[71]|abstract|abstract[73]	new[71]|giv|new[73]	_	_
11-23	1730-1740	management	abstract[71]|abstract[73]	new[71]|new[73]	_	_
11-24	1741-1742	.	_	_	_	_

#Text=Still , different challenges remain in anti-HIV drug therapy/prophylaxis , and these include the following , among others : ( i ) the onset of severe adverse effects leading to the discontinuation or interruption of therapy or even prophylaxis ; ( ii ) sub-optimal biodistribution and pharmacokinetics , particularly in reservoir sites or mucosae involved in sexual transmission ; ( iii ) the occurrence of viral resistance ; ( iv ) troublesome regimens and/or drug delivery routes that lead to poor adherence by patients/users ; ( v ) low stability and reduced shelf-life of active molecules , which may be particularly challenging in tropical climates and low-resource regions lacking adequate refrigerated distribution channels and storage ; ( vi ) lack of suitable dosage forms for particular populations ( e. g. , children and women ) ; ( vii ) costly drug products that are often inaccessible to populations in need of therapy/prophylaxis ; and ( viii ) social and legal constraints resulting in poor access to and the discontinuation of anti-HIV therapy/prophylaxis .
12-1	1743-1748	Still	_	_	_	_
12-2	1749-1750	,	_	_	_	_
12-3	1751-1760	different	abstract[74]	new[74]	ana	12-12[0_74]
12-4	1761-1771	challenges	abstract[74]	new[74]	_	_
12-5	1772-1778	remain	_	_	_	_
12-6	1779-1781	in	_	_	_	_
12-7	1782-1790	anti-HIV	abstract|abstract[77]	new|new[77]	coref|coref	12-152[0_77]|12-171
12-8	1791-1795	drug	substance|abstract[77]	new|new[77]	coref	12-75
12-9	1796-1815	therapy/prophylaxis	abstract[77]	new[77]	_	_
12-10	1816-1817	,	_	_	_	_
12-11	1818-1821	and	_	_	_	_
12-12	1822-1827	these	abstract	giv	coref	14-18[136_0]
12-13	1828-1835	include	_	_	_	_
12-14	1836-1839	the	_	_	_	_
12-15	1840-1849	following	_	_	_	_
12-16	1850-1851	,	_	_	_	_
12-17	1852-1857	among	_	_	_	_
12-18	1858-1864	others	_	_	_	_
12-19	1865-1866	:	_	_	_	_
12-20	1867-1868	(	_	_	_	_
12-21	1869-1870	i	_	_	_	_
12-22	1871-1872	)	_	_	_	_
12-23	1873-1876	the	abstract[79]	new[79]	_	_
12-24	1877-1882	onset	abstract[79]	new[79]	_	_
12-25	1883-1885	of	abstract[79]	new[79]	_	_
12-26	1886-1892	severe	abstract[79]|abstract[81]	new[79]|new[81]	_	_
12-27	1893-1900	adverse	abstract[79]|abstract|abstract[81]	new[79]|new|new[81]	_	_
12-28	1901-1908	effects	abstract[79]|abstract[81]	new[79]|new[81]	_	_
12-29	1909-1916	leading	_	_	_	_
12-30	1917-1919	to	_	_	_	_
12-31	1920-1923	the	event[82]	new[82]	coref	12-168[125_82]
12-32	1924-1939	discontinuation	event[82]	new[82]	_	_
12-33	1940-1942	or	_	_	_	_
12-34	1943-1955	interruption	abstract[83]	new[83]	_	_
12-35	1956-1958	of	abstract[83]	new[83]	_	_
12-36	1959-1966	therapy	abstract[83]|abstract|abstract[85]	new[83]|giv|giv[85]	coref|coref	16-4[153_0]|16-4[154_85]
12-37	1967-1969	or	abstract[83]|abstract[85]	new[83]|giv[85]	_	_
12-38	1970-1974	even	abstract[83]|abstract[85]|abstract[86]|abstract[87]	new[83]|giv[85]|giv[86]|giv[87]	_	_
12-39	1975-1986	prophylaxis	abstract[83]|abstract[85]|abstract[86]|abstract[87]	new[83]|giv[85]|giv[86]|giv[87]	_	_
12-40	1987-1988	;	abstract[83]|abstract[85]|abstract[87]	new[83]|giv[85]|giv[87]	_	_
12-41	1989-1990	(	abstract[83]|abstract[85]|abstract[87]	new[83]|giv[85]|giv[87]	_	_
12-42	1991-1993	ii	abstract[83]|abstract[85]|abstract[87]	new[83]|giv[85]|giv[87]	_	_
12-43	1994-1995	)	abstract[83]|abstract[85]|abstract[87]	new[83]|giv[85]|giv[87]	_	_
12-44	1996-2007	sub-optimal	abstract[83]|abstract[85]|abstract[87]|abstract[88]	new[83]|giv[85]|giv[87]|new[88]	_	_
12-45	2008-2023	biodistribution	abstract[83]|abstract[85]|abstract[87]|abstract[88]	new[83]|giv[85]|giv[87]|new[88]	_	_
12-46	2024-2027	and	abstract[83]|abstract[85]|abstract[87]	new[83]|giv[85]|giv[87]	_	_
12-47	2028-2044	pharmacokinetics	abstract[83]|abstract[85]|abstract[87]|abstract[89]	new[83]|giv[85]|giv[87]|new[89]	_	_
12-48	2045-2046	,	abstract[83]|abstract[85]|abstract[87]|abstract[89]	new[83]|giv[85]|giv[87]|new[89]	_	_
12-49	2047-2059	particularly	abstract[83]|abstract[85]|abstract[87]|abstract[89]|place[91]	new[83]|giv[85]|giv[87]|new[89]|new[91]	_	_
12-50	2060-2062	in	abstract[83]|abstract[85]|abstract[87]|abstract[89]|place[91]	new[83]|giv[85]|giv[87]|new[89]|new[91]	_	_
12-51	2063-2072	reservoir	abstract[83]|abstract[85]|abstract[87]|abstract[89]|place|place[91]	new[83]|giv[85]|giv[87]|new[89]|new|new[91]	_	_
12-52	2073-2078	sites	abstract[83]|abstract[85]|abstract[87]|abstract[89]|place[91]	new[83]|giv[85]|giv[87]|new[89]|new[91]	_	_
12-53	2079-2081	or	abstract[83]|abstract[85]|abstract[87]|abstract[89]	new[83]|giv[85]|giv[87]|new[89]	_	_
12-54	2082-2089	mucosae	abstract[83]|abstract[85]|abstract[87]|abstract[89]|object	new[83]|giv[85]|giv[87]|new[89]|new	_	_
12-55	2090-2098	involved	_	_	_	_
12-56	2099-2101	in	_	_	_	_
12-57	2102-2108	sexual	abstract[93]	giv[93]	_	_
12-58	2109-2121	transmission	abstract[93]	giv[93]	_	_
12-59	2122-2123	;	_	_	_	_
12-60	2124-2125	(	_	_	_	_
12-61	2126-2129	iii	_	_	_	_
12-62	2130-2131	)	_	_	_	_
12-63	2132-2135	the	abstract[94]	new[94]	_	_
12-64	2136-2146	occurrence	abstract[94]	new[94]	_	_
12-65	2147-2149	of	abstract[94]	new[94]	_	_
12-66	2150-2155	viral	abstract[94]|abstract[95]	new[94]|new[95]	_	_
12-67	2156-2166	resistance	abstract[94]|abstract[95]	new[94]|new[95]	_	_
12-68	2167-2168	;	abstract[94]	new[94]	_	_
12-69	2169-2170	(	abstract[94]	new[94]	_	_
12-70	2171-2173	iv	abstract[94]	new[94]	_	_
12-71	2174-2175	)	abstract[94]	new[94]	_	_
12-72	2176-2187	troublesome	abstract[94]|abstract[96]	new[94]|new[96]	_	_
12-73	2188-2196	regimens	abstract[94]|abstract[96]	new[94]|new[96]	_	_
12-74	2197-2203	and/or	abstract[94]|abstract[96]	new[94]|new[96]	_	_
12-75	2204-2208	drug	abstract[94]|abstract[96]|substance|abstract[99]	new[94]|new[96]|giv|new[99]	coref	12-141
12-76	2209-2217	delivery	abstract[94]|abstract[96]|abstract|abstract[99]	new[94]|new[96]|new|new[99]	coref	15-41[150_0]
12-77	2218-2224	routes	abstract[94]|abstract[96]|abstract[99]	new[94]|new[96]|new[99]	_	_
12-78	2225-2229	that	_	_	_	_
12-79	2230-2234	lead	_	_	_	_
12-80	2235-2237	to	_	_	_	_
12-81	2238-2242	poor	abstract[100]	new[100]	_	_
12-82	2243-2252	adherence	abstract[100]	new[100]	_	_
12-83	2253-2255	by	abstract[100]	new[100]	_	_
12-84	2256-2270	patients/users	abstract[100]|person[101]	new[100]|new[101]	_	_
12-85	2271-2272	;	abstract[100]|person[101]	new[100]|new[101]	_	_
12-86	2273-2274	(	abstract[100]|person[101]	new[100]|new[101]	_	_
12-87	2275-2276	v	abstract[100]|person[101]|abstract	new[100]|new[101]|new	_	_
12-88	2277-2278	)	abstract[100]|person[101]	new[100]|new[101]	_	_
12-89	2279-2282	low	abstract[100]|abstract[103]	new[100]|new[103]	_	_
12-90	2283-2292	stability	abstract[100]|abstract[103]	new[100]|new[103]	_	_
12-91	2293-2296	and	abstract[100]	new[100]	_	_
12-92	2297-2304	reduced	abstract[100]|abstract[104]	new[100]|new[104]	_	_
12-93	2305-2315	shelf-life	abstract[100]|abstract[104]	new[100]|new[104]	_	_
12-94	2316-2318	of	abstract[100]|abstract[104]	new[100]|new[104]	_	_
12-95	2319-2325	active	abstract[100]|abstract[104]|object[105]	new[100]|new[104]|new[105]	_	_
12-96	2326-2335	molecules	abstract[100]|abstract[104]|object[105]	new[100]|new[104]|new[105]	_	_
12-97	2336-2337	,	_	_	_	_
12-98	2338-2343	which	_	_	_	_
12-99	2344-2347	may	_	_	_	_
12-100	2348-2350	be	_	_	_	_
12-101	2351-2363	particularly	_	_	_	_
12-102	2364-2375	challenging	_	_	_	_
12-103	2376-2378	in	_	_	_	_
12-104	2379-2387	tropical	abstract[106]	new[106]	_	_
12-105	2388-2396	climates	abstract[106]	new[106]	_	_
12-106	2397-2400	and	_	_	_	_
12-107	2401-2413	low-resource	place[107]	new[107]	_	_
12-108	2414-2421	regions	place[107]	new[107]	_	_
12-109	2422-2429	lacking	_	_	_	_
12-110	2430-2438	adequate	place[109]	new[109]	_	_
12-111	2439-2451	refrigerated	place[109]	new[109]	_	_
12-112	2452-2464	distribution	abstract|place[109]	new|new[109]	_	_
12-113	2465-2473	channels	place[109]	new[109]	_	_
12-114	2474-2477	and	_	_	_	_
12-115	2478-2485	storage	place	new	_	_
12-116	2486-2487	;	_	_	_	_
12-117	2488-2489	(	_	_	_	_
12-118	2490-2492	vi	_	_	_	_
12-119	2493-2494	)	_	_	_	_
12-120	2495-2499	lack	abstract[111]	new[111]	_	_
12-121	2500-2502	of	abstract[111]	new[111]	_	_
12-122	2503-2511	suitable	abstract[111]|abstract[113]	new[111]|new[113]	_	_
12-123	2512-2518	dosage	abstract[111]|quantity|abstract[113]	new[111]|new|new[113]	_	_
12-124	2519-2524	forms	abstract[111]|abstract[113]	new[111]|new[113]	_	_
12-125	2525-2528	for	abstract[111]|abstract[113]	new[111]|new[113]	_	_
12-126	2529-2539	particular	abstract[111]|abstract[113]|person[114]	new[111]|new[113]|new[114]	coref	12-148[119_114]
12-127	2540-2551	populations	abstract[111]|abstract[113]|person[114]	new[111]|new[113]|new[114]	_	_
12-128	2552-2553	(	abstract[111]|abstract[113]	new[111]|new[113]	_	_
12-129	2554-2556	e.	abstract[111]|abstract[113]|abstract	new[111]|new[113]|new	_	_
12-130	2557-2559	g.	abstract[111]|abstract[113]	new[111]|new[113]	_	_
12-131	2560-2561	,	abstract[111]|abstract[113]	new[111]|new[113]	_	_
12-132	2562-2570	children	abstract[111]|abstract[113]	new[111]|new[113]	_	_
12-133	2571-2574	and	abstract[111]|abstract[113]	new[111]|new[113]	_	_
12-134	2575-2580	women	abstract[111]|abstract[113]	new[111]|new[113]	_	_
12-135	2581-2582	)	abstract[111]|abstract[113]	new[111]|new[113]	_	_
12-136	2583-2584	;	abstract[111]|abstract[113]	new[111]|new[113]	_	_
12-137	2585-2586	(	abstract[111]|abstract[113]	new[111]|new[113]	_	_
12-138	2587-2590	vii	abstract[111]|abstract[113]|abstract	new[111]|new[113]|new	_	_
12-139	2591-2592	)	abstract[111]|abstract[113]	new[111]|new[113]	_	_
12-140	2593-2599	costly	abstract[111]|abstract[113]|object[118]	new[111]|new[113]|giv[118]	coref	14-4[133_118]
12-141	2600-2604	drug	abstract[111]|abstract[113]|substance|object[118]	new[111]|new[113]|giv|giv[118]	coref	15-29
12-142	2605-2613	products	abstract[111]|abstract[113]|object[118]	new[111]|new[113]|giv[118]	_	_
12-143	2614-2618	that	_	_	_	_
12-144	2619-2622	are	_	_	_	_
12-145	2623-2628	often	_	_	_	_
12-146	2629-2641	inaccessible	_	_	_	_
12-147	2642-2644	to	_	_	_	_
12-148	2645-2656	populations	person[119]	giv[119]	_	_
12-149	2657-2659	in	person[119]	giv[119]	_	_
12-150	2660-2664	need	person[119]|abstract[120]	giv[119]|new[120]	_	_
12-151	2665-2667	of	person[119]|abstract[120]	giv[119]|new[120]	_	_
12-152	2668-2687	therapy/prophylaxis	person[119]|abstract[120]|abstract	giv[119]|new[120]|giv	coref	12-171[127_0]
12-153	2688-2689	;	_	_	_	_
12-154	2690-2693	and	_	_	_	_
12-155	2694-2695	(	_	_	_	_
12-156	2696-2700	viii	abstract	new	_	_
12-157	2701-2702	)	_	_	_	_
12-158	2703-2709	social	_	_	_	_
12-159	2710-2713	and	_	_	_	_
12-160	2714-2719	legal	abstract[123]	new[123]	_	_
12-161	2720-2731	constraints	abstract[123]	new[123]	_	_
12-162	2732-2741	resulting	_	_	_	_
12-163	2742-2744	in	_	_	_	_
12-164	2745-2749	poor	abstract[124]	new[124]	_	_
12-165	2750-2756	access	abstract[124]	new[124]	_	_
12-166	2757-2759	to	_	_	_	_
12-167	2760-2763	and	_	_	_	_
12-168	2764-2767	the	event[125]	giv[125]	_	_
12-169	2768-2783	discontinuation	event[125]	giv[125]	_	_
12-170	2784-2786	of	event[125]	giv[125]	_	_
12-171	2787-2795	anti-HIV	event[125]|abstract|abstract[127]	giv[125]|giv|giv[127]	coref|coref	17-19[161_127]|19-11
12-172	2796-2815	therapy/prophylaxis	event[125]|abstract[127]	giv[125]|giv[127]	_	_
12-173	2816-2817	.	_	_	_	_

#Text=The response from the scientific community could not be more affirmative , and novel ideas and concepts have been emerging throughout the last decade or so .
13-1	2818-2821	The	abstract[128]	new[128]	_	_
13-2	2822-2830	response	abstract[128]	new[128]	_	_
13-3	2831-2835	from	abstract[128]	new[128]	_	_
13-4	2836-2839	the	abstract[128]|organization[129]	new[128]|new[129]	_	_
13-5	2840-2850	scientific	abstract[128]|organization[129]	new[128]|new[129]	_	_
13-6	2851-2860	community	abstract[128]|organization[129]	new[128]|new[129]	_	_
13-7	2861-2866	could	_	_	_	_
13-8	2867-2870	not	_	_	_	_
13-9	2871-2873	be	_	_	_	_
13-10	2874-2878	more	_	_	_	_
13-11	2879-2890	affirmative	_	_	_	_
13-12	2891-2892	,	_	_	_	_
13-13	2893-2896	and	_	_	_	_
13-14	2897-2902	novel	abstract[130]	new[130]	_	_
13-15	2903-2908	ideas	abstract[130]	new[130]	_	_
13-16	2909-2912	and	_	_	_	_
13-17	2913-2921	concepts	abstract	new	_	_
13-18	2922-2926	have	_	_	_	_
13-19	2927-2931	been	_	_	_	_
13-20	2932-2940	emerging	_	_	_	_
13-21	2941-2951	throughout	_	_	_	_
13-22	2952-2955	the	time[132]	new[132]	_	_
13-23	2956-2960	last	time[132]	new[132]	_	_
13-24	2961-2967	decade	time[132]	new[132]	_	_
13-25	2968-2970	or	_	_	_	_
13-26	2971-2973	so	_	_	_	_
13-27	2974-2975	.	_	_	_	_

#Text=More important , innovative products are now under development , holding great promise for mitigating many of the challenges identified above .
14-1	2976-2980	More	_	_	_	_
14-2	2981-2990	important	_	_	_	_
14-3	2991-2992	,	_	_	_	_
14-4	2993-3003	innovative	object[133]	giv[133]	coref	15-28[147_133]
14-5	3004-3012	products	object[133]	giv[133]	_	_
14-6	3013-3016	are	_	_	_	_
14-7	3017-3020	now	abstract[134]	giv[134]	_	_
14-8	3021-3026	under	abstract[134]	giv[134]	_	_
14-9	3027-3038	development	abstract[134]	giv[134]	_	_
14-10	3039-3040	,	_	_	_	_
14-11	3041-3048	holding	_	_	_	_
14-12	3049-3054	great	abstract[135]	new[135]	_	_
14-13	3055-3062	promise	abstract[135]	new[135]	_	_
14-14	3063-3066	for	_	_	_	_
14-15	3067-3077	mitigating	_	_	_	_
14-16	3078-3082	many	_	_	_	_
14-17	3083-3085	of	_	_	_	_
14-18	3086-3089	the	abstract[136]	giv[136]	_	_
14-19	3090-3100	challenges	abstract[136]	giv[136]	_	_
14-20	3101-3111	identified	_	_	_	_
14-21	3112-3117	above	_	_	_	_
14-22	3118-3119	.	_	_	_	_

#Text=This Special Issue presents an exciting series of reviews and original research articles from eminent scientists in academia and different nonprofit organizations involved in the development of antiretroviral drug products , focusing mainly on novel strategies for the formulation and delivery of anti-HIV compounds .
15-1	3120-3124	This	abstract[137]	new[137]	coref	18-1[167_137]
15-2	3125-3132	Special	abstract[137]	new[137]	_	_
15-3	3133-3138	Issue	abstract[137]	new[137]	_	_
15-4	3139-3147	presents	_	_	_	_
15-5	3148-3150	an	abstract[138]	new[138]	_	_
15-6	3151-3159	exciting	abstract[138]	new[138]	_	_
15-7	3160-3166	series	abstract[138]	new[138]	_	_
15-8	3167-3169	of	abstract[138]	new[138]	_	_
15-9	3170-3177	reviews	abstract[138]|abstract	new[138]|new	_	_
15-10	3178-3181	and	abstract[138]	new[138]	_	_
15-11	3182-3190	original	abstract[138]|abstract[141]	new[138]|new[141]	_	_
15-12	3191-3199	research	abstract[138]|abstract|abstract[141]	new[138]|new|new[141]	_	_
15-13	3200-3208	articles	abstract[138]|abstract[141]	new[138]|new[141]	_	_
15-14	3209-3213	from	abstract[138]|abstract[141]	new[138]|new[141]	_	_
15-15	3214-3221	eminent	abstract[138]|abstract[141]|person[142]	new[138]|new[141]|new[142]	_	_
15-16	3222-3232	scientists	abstract[138]|abstract[141]|person[142]	new[138]|new[141]|new[142]	_	_
15-17	3233-3235	in	abstract[138]|abstract[141]|person[142]	new[138]|new[141]|new[142]	_	_
15-18	3236-3244	academia	abstract[138]|abstract[141]|person[142]|organization	new[138]|new[141]|new[142]|new	_	_
15-19	3245-3248	and	abstract[138]|abstract[141]|person[142]	new[138]|new[141]|new[142]	_	_
15-20	3249-3258	different	abstract[138]|abstract[141]|person[142]|organization[144]	new[138]|new[141]|new[142]|new[144]	_	_
15-21	3259-3268	nonprofit	abstract[138]|abstract[141]|person[142]|organization[144]	new[138]|new[141]|new[142]|new[144]	_	_
15-22	3269-3282	organizations	abstract[138]|abstract[141]|person[142]|organization[144]	new[138]|new[141]|new[142]|new[144]	_	_
15-23	3283-3291	involved	_	_	_	_
15-24	3292-3294	in	_	_	_	_
15-25	3295-3298	the	abstract[145]	new[145]	_	_
15-26	3299-3310	development	abstract[145]	new[145]	_	_
15-27	3311-3313	of	abstract[145]	new[145]	_	_
15-28	3314-3328	antiretroviral	abstract[145]|object[147]	new[145]|giv[147]	coref	17-31[165_147]
15-29	3329-3333	drug	abstract[145]|substance|object[147]	new[145]|giv|giv[147]	coref	17-22
15-30	3334-3342	products	abstract[145]|object[147]	new[145]|giv[147]	_	_
15-31	3343-3344	,	_	_	_	_
15-32	3345-3353	focusing	_	_	_	_
15-33	3354-3360	mainly	_	_	_	_
15-34	3361-3363	on	_	_	_	_
15-35	3364-3369	novel	abstract[148]	new[148]	coref	18-18[0_148]
15-36	3370-3380	strategies	abstract[148]	new[148]	_	_
15-37	3381-3384	for	abstract[148]	new[148]	_	_
15-38	3385-3388	the	abstract[148]|abstract[149]	new[148]|new[149]	_	_
15-39	3389-3400	formulation	abstract[148]|abstract[149]	new[148]|new[149]	_	_
15-40	3401-3404	and	abstract[148]	new[148]	_	_
15-41	3405-3413	delivery	abstract[148]|abstract[150]	new[148]|giv[150]	coref	17-22[163_150]
15-42	3414-3416	of	abstract[148]|abstract[150]	new[148]|giv[150]	_	_
15-43	3417-3425	anti-HIV	abstract[148]|abstract[150]|object[151]	new[148]|giv[150]|new[151]	_	_
15-44	3426-3435	compounds	abstract[148]|abstract[150]|object[151]	new[148]|giv[150]|new[151]	_	_
15-45	3436-3437	.	_	_	_	_

#Text=Innovative approaches towards improved gene therapy and immunotherapy are also addressed .
16-1	3438-3448	Innovative	abstract[152]	new[152]	coref	19-19[185_152]
16-2	3449-3459	approaches	abstract[152]	new[152]	_	_
16-3	3460-3467	towards	abstract[152]	new[152]	_	_
16-4	3468-3476	improved	abstract[152]|abstract[153]|abstract[154]	new[152]|giv[153]|giv[154]	coref	18-28[177_153]
16-5	3477-3481	gene	abstract[152]|abstract[153]|abstract[154]	new[152]|giv[153]|giv[154]	_	_
16-6	3482-3489	therapy	abstract[152]|abstract[153]|abstract[154]	new[152]|giv[153]|giv[154]	_	_
16-7	3490-3493	and	abstract[152]|abstract[154]	new[152]|giv[154]	_	_
16-8	3494-3507	immunotherapy	abstract[152]|abstract[154]|abstract	new[152]|giv[154]|new	_	_
16-9	3508-3511	are	_	_	_	_
16-10	3512-3516	also	_	_	_	_
16-11	3517-3526	addressed	_	_	_	_
16-12	3527-3528	.	_	_	_	_

#Text=The presented reports provide not only interesting overviews and opinion on recent developments in the broad field of antiretroviral therapy/prophylaxis and drug delivery , but also describe the development of new products that are currently tracked for clinical testing .
17-1	3529-3532	The	abstract[156]	new[156]	_	_
17-2	3533-3542	presented	abstract[156]	new[156]	_	_
17-3	3543-3550	reports	abstract[156]	new[156]	_	_
17-4	3551-3558	provide	_	_	_	_
17-5	3559-3562	not	_	_	_	_
17-6	3563-3567	only	abstract[157]	new[157]	_	_
17-7	3568-3579	interesting	abstract[157]	new[157]	_	_
17-8	3580-3589	overviews	abstract[157]	new[157]	_	_
17-9	3590-3593	and	_	_	_	_
17-10	3594-3601	opinion	abstract[158]	new[158]	_	_
17-11	3602-3604	on	abstract[158]	new[158]	_	_
17-12	3605-3611	recent	abstract[158]|abstract[159]	new[158]|new[159]	_	_
17-13	3612-3624	developments	abstract[158]|abstract[159]	new[158]|new[159]	_	_
17-14	3625-3627	in	abstract[158]|abstract[159]	new[158]|new[159]	_	_
17-15	3628-3631	the	abstract[158]|abstract[159]|abstract[160]	new[158]|new[159]|giv[160]	coref	20-3[190_160]
17-16	3632-3637	broad	abstract[158]|abstract[159]|abstract[160]	new[158]|new[159]|giv[160]	_	_
17-17	3638-3643	field	abstract[158]|abstract[159]|abstract[160]	new[158]|new[159]|giv[160]	_	_
17-18	3644-3646	of	abstract[158]|abstract[159]|abstract[160]	new[158]|new[159]|giv[160]	_	_
17-19	3647-3661	antiretroviral	abstract[158]|abstract[159]|abstract[160]|abstract[161]	new[158]|new[159]|giv[160]|giv[161]	_	_
17-20	3662-3681	therapy/prophylaxis	abstract[158]|abstract[159]|abstract[160]|abstract[161]	new[158]|new[159]|giv[160]|giv[161]	_	_
17-21	3682-3685	and	abstract[158]|abstract[159]|abstract[160]	new[158]|new[159]|giv[160]	_	_
17-22	3686-3690	drug	abstract[158]|abstract[159]|abstract[160]|substance|abstract[163]	new[158]|new[159]|giv[160]|giv|giv[163]	_	_
17-23	3691-3699	delivery	abstract[158]|abstract[159]|abstract[160]|abstract[163]	new[158]|new[159]|giv[160]|giv[163]	_	_
17-24	3700-3701	,	_	_	_	_
17-25	3702-3705	but	_	_	_	_
17-26	3706-3710	also	_	_	_	_
17-27	3711-3719	describe	_	_	_	_
17-28	3720-3723	the	abstract[164]	new[164]	_	_
17-29	3724-3735	development	abstract[164]	new[164]	_	_
17-30	3736-3738	of	abstract[164]	new[164]	_	_
17-31	3739-3742	new	abstract[164]|object[165]	new[164]|giv[165]	_	_
17-32	3743-3751	products	abstract[164]|object[165]	new[164]|giv[165]	_	_
17-33	3752-3756	that	_	_	_	_
17-34	3757-3760	are	_	_	_	_
17-35	3761-3770	currently	_	_	_	_
17-36	3771-3778	tracked	_	_	_	_
17-37	3779-3782	for	_	_	_	_
17-38	3783-3791	clinical	abstract[166]	new[166]	_	_
17-39	3792-3799	testing	abstract[166]	new[166]	_	_
17-40	3800-3801	.	_	_	_	_

#Text=The Special Issue starts with an interesting review by Tsukamoto at Kindai University , Japan , on strategies explored for curing HIV infection using a combination of gene therapy and host immunization .
18-1	3802-3805	The	abstract[167]	giv[167]	_	_
18-2	3806-3813	Special	abstract[167]	giv[167]	_	_
18-3	3814-3819	Issue	abstract[167]	giv[167]	_	_
18-4	3820-3826	starts	_	_	_	_
18-5	3827-3831	with	_	_	_	_
18-6	3832-3834	an	abstract[168]	new[168]	coref	20-20[196_168]
18-7	3835-3846	interesting	abstract[168]	new[168]	_	_
18-8	3847-3853	review	abstract[168]	new[168]	_	_
18-9	3854-3856	by	abstract[168]	new[168]	_	_
18-10	3857-3866	Tsukamoto	abstract[168]|person	new[168]|new	_	_
18-11	3867-3869	at	_	_	_	_
18-12	3870-3876	Kindai	person|organization[171]	new|new[171]	coref	20-11[193_171]
18-13	3877-3887	University	organization[171]	new[171]	_	_
18-14	3888-3889	,	organization[171]	new[171]	_	_
18-15	3890-3895	Japan	organization[171]|place	new[171]|new	_	_
18-16	3896-3897	,	_	_	_	_
18-17	3898-3900	on	_	_	_	_
18-18	3901-3911	strategies	abstract	giv	_	_
18-19	3912-3920	explored	_	_	_	_
18-20	3921-3924	for	_	_	_	_
18-21	3925-3931	curing	_	_	_	_
18-22	3932-3935	HIV	abstract|abstract[175]	giv|giv[175]	coref	20-34
18-23	3936-3945	infection	abstract[175]	giv[175]	_	_
18-24	3946-3951	using	_	_	_	_
18-25	3952-3953	a	abstract[176]	giv[176]	_	_
18-26	3954-3965	combination	abstract[176]	giv[176]	_	_
18-27	3966-3968	of	abstract[176]	giv[176]	_	_
18-28	3969-3973	gene	abstract[176]|abstract[177]	giv[176]|giv[177]	coref	21-14[203_177]
18-29	3974-3981	therapy	abstract[176]|abstract[177]	giv[176]|giv[177]	_	_
18-30	3982-3985	and	_	_	_	_
18-31	3986-3990	host	_	_	_	_
18-32	3991-4003	immunization	abstract	new	coref	19-11[182_0]
18-33	4004-4005	.	_	_	_	_

#Text=In particular , the author emphasizes the possible role of anti-HIV intracellular immunization using gene silencing , among other approaches , in the protection of bone marrow hematopoietic stem/progenitor cells .
19-1	4006-4008	In	_	_	_	_
19-2	4009-4019	particular	_	_	_	_
19-3	4020-4021	,	_	_	_	_
19-4	4022-4025	the	person[179]	new[179]	_	_
19-5	4026-4032	author	person[179]	new[179]	_	_
19-6	4033-4043	emphasizes	_	_	_	_
19-7	4044-4047	the	abstract[180]	new[180]	_	_
19-8	4048-4056	possible	abstract[180]	new[180]	_	_
19-9	4057-4061	role	abstract[180]	new[180]	_	_
19-10	4062-4064	of	abstract[180]	new[180]	_	_
19-11	4065-4073	anti-HIV	abstract[180]|abstract|abstract[182]	new[180]|giv|giv[182]	_	_
19-12	4074-4087	intracellular	abstract[180]|abstract[182]	new[180]|giv[182]	_	_
19-13	4088-4100	immunization	abstract[180]|abstract[182]	new[180]|giv[182]	_	_
19-14	4101-4106	using	_	_	_	_
19-15	4107-4111	gene	abstract|abstract[184]	new|new[184]	_	_
19-16	4112-4121	silencing	abstract[184]	new[184]	_	_
19-17	4122-4123	,	_	_	_	_
19-18	4124-4129	among	_	_	_	_
19-19	4130-4135	other	abstract[185]	giv[185]	_	_
19-20	4136-4146	approaches	abstract[185]	giv[185]	_	_
19-21	4147-4148	,	_	_	_	_
19-22	4149-4151	in	_	_	_	_
19-23	4152-4155	the	abstract[186]	new[186]	_	_
19-24	4156-4166	protection	abstract[186]	new[186]	_	_
19-25	4167-4169	of	abstract[186]	new[186]	_	_
19-26	4170-4174	bone	abstract[186]|object[189]	new[186]|new[189]	coref	21-19[204_189]
19-27	4175-4181	marrow	abstract[186]|animal|object[189]	new[186]|new|new[189]	_	_
19-28	4182-4195	hematopoietic	abstract[186]|object[189]	new[186]|new[189]	_	_
19-29	4196-4211	stem/progenitor	abstract[186]|object|object[189]	new[186]|new|new[189]	_	_
19-30	4212-4217	cells	abstract[186]|object[189]	new[186]|new[189]	_	_
19-31	4218-4219	.	_	_	_	_

#Text=Still in the same field , Düzgüneş and Konopka at the University of the Pacific , USA , contributed a stimulating review on a potential strategy for the eradication of cellular reservoirs of HIV .
20-1	4220-4225	Still	_	_	_	_
20-2	4226-4228	in	_	_	_	_
20-3	4229-4232	the	abstract[190]	giv[190]	_	_
20-4	4233-4237	same	abstract[190]	giv[190]	_	_
20-5	4238-4243	field	abstract[190]	giv[190]	_	_
20-6	4244-4245	,	_	_	_	_
20-7	4246-4254	Düzgüneş	person	new	_	_
20-8	4255-4258	and	_	_	_	_
20-9	4259-4266	Konopka	person[192]	new[192]	_	_
20-10	4267-4269	at	person[192]	new[192]	_	_
20-11	4270-4273	the	person[192]|organization[193]	new[192]|giv[193]	_	_
20-12	4274-4284	University	person[192]|organization[193]	new[192]|giv[193]	_	_
20-13	4285-4287	of	person[192]|organization[193]	new[192]|giv[193]	_	_
20-14	4288-4291	the	person[192]|organization[193]|place[194]	new[192]|giv[193]|new[194]	_	_
20-15	4292-4299	Pacific	person[192]|organization[193]|place[194]	new[192]|giv[193]|new[194]	_	_
20-16	4300-4301	,	person[192]|organization[193]|place[194]	new[192]|giv[193]|new[194]	_	_
20-17	4302-4305	USA	person[192]|organization[193]|place[194]|place	new[192]|giv[193]|new[194]|new	_	_
20-18	4306-4307	,	_	_	_	_
20-19	4308-4319	contributed	_	_	_	_
20-20	4320-4321	a	abstract[196]	giv[196]	_	_
20-21	4322-4333	stimulating	abstract[196]	giv[196]	_	_
20-22	4334-4340	review	abstract[196]	giv[196]	_	_
20-23	4341-4343	on	_	_	_	_
20-24	4344-4345	a	abstract[197]	new[197]	_	_
20-25	4346-4355	potential	abstract[197]	new[197]	_	_
20-26	4356-4364	strategy	abstract[197]	new[197]	_	_
20-27	4365-4368	for	abstract[197]	new[197]	_	_
20-28	4369-4372	the	abstract[197]|abstract[198]	new[197]|new[198]	_	_
20-29	4373-4384	eradication	abstract[197]|abstract[198]	new[197]|new[198]	_	_
20-30	4385-4387	of	abstract[197]|abstract[198]	new[197]|new[198]	_	_
20-31	4388-4396	cellular	abstract[197]|abstract[198]|abstract[199]	new[197]|new[198]|new[199]	_	_
20-32	4397-4407	reservoirs	abstract[197]|abstract[198]|abstract[199]	new[197]|new[198]|new[199]	_	_
20-33	4408-4410	of	abstract[197]|abstract[198]|abstract[199]	new[197]|new[198]|new[199]	_	_
20-34	4411-4414	HIV	abstract[197]|abstract[198]|abstract[199]|abstract	new[197]|new[198]|new[199]|giv	_	_
20-35	4415-4416	.	_	_	_	_

#Text=This thought-provoking piece explores how such an objective could be achieved by using suicide gene therapy for killing HIV-infected cells , excision of chromosome-integrated viral DNA , and cytotoxic liposomes targeted to latency-reversed HIV-infected cells .
21-1	4417-4421	This	abstract[201]	new[201]	_	_
21-2	4422-4439	thought-provoking	abstract[201]	new[201]	_	_
21-3	4440-4445	piece	abstract[201]	new[201]	_	_
21-4	4446-4454	explores	_	_	_	_
21-5	4455-4458	how	_	_	_	_
21-6	4459-4463	such	event[202]	new[202]	_	_
21-7	4464-4466	an	event[202]	new[202]	_	_
21-8	4467-4476	objective	event[202]	new[202]	_	_
21-9	4477-4482	could	_	_	_	_
21-10	4483-4485	be	_	_	_	_
21-11	4486-4494	achieved	_	_	_	_
21-12	4495-4497	by	_	_	_	_
21-13	4498-4503	using	_	_	_	_
21-14	4504-4511	suicide	abstract[203]	giv[203]	_	_
21-15	4512-4516	gene	abstract[203]	giv[203]	_	_
21-16	4517-4524	therapy	abstract[203]	giv[203]	_	_
21-17	4525-4528	for	_	_	_	_
21-18	4529-4536	killing	_	_	_	_
21-19	4537-4549	HIV-infected	object[204]	giv[204]	coref	21-33[209_204]
21-20	4550-4555	cells	object[204]	giv[204]	_	_
21-21	4556-4557	,	object[204]	giv[204]	_	_
21-22	4558-4566	excision	object[204]|event[205]	giv[204]|new[205]	_	_
21-23	4567-4569	of	object[204]|event[205]	giv[204]|new[205]	_	_
21-24	4570-4591	chromosome-integrated	object[204]|event[205]|substance[206]	giv[204]|new[205]|new[206]	_	_
21-25	4592-4597	viral	object[204]|event[205]|substance[206]	giv[204]|new[205]|new[206]	_	_
21-26	4598-4601	DNA	object[204]|event[205]|substance[206]	giv[204]|new[205]|new[206]	_	_
21-27	4602-4603	,	object[204]	giv[204]	_	_
21-28	4604-4607	and	object[204]	giv[204]	_	_
21-29	4608-4617	cytotoxic	object[204]|abstract|object[208]	giv[204]|new|new[208]	_	_
21-30	4618-4627	liposomes	object[204]|object[208]	giv[204]|new[208]	_	_
21-31	4628-4636	targeted	_	_	_	_
21-32	4637-4639	to	_	_	_	_
21-33	4640-4656	latency-reversed	object[209]	giv[209]	_	_
21-34	4657-4669	HIV-infected	object[209]	giv[209]	_	_
21-35	4670-4675	cells	object[209]	giv[209]	_	_
21-36	4676-4677	.	_	_	_	_
